Treats itching of the eye associated with allergic conjunctivitis. ANDA 210092, held by Gland. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 210092 (Azelastine Hydrochloride), held by Gland, was first approved by FDA on Feb 25, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Azelastine hydrochloride ophthalmic solution is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 25, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.05% · solution/drops;ophthalmic | Azelastine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters